Galapagos and OneWorld Health collaborate to develop new drugs for the treatment of diarrheal diseases

08-Sep-2006

Galapagos NV announced that its service division BioFocus DPI has entered into a drug discovery collaboration with the Institute for OneWorld Health, a non-profit pharmaceutical company. OneWorld Health is working on a number of drug development initiatives for neglected diseases, with support from the Bill & Melinda Gates Foundation and other donors. The collaboration focuses on the development of new drugs to combat diarrheal diseases, a fundamental threat to the health of children in the developing world. Under the terms of the agreement, BioFocus DPI will apply its medicinal chemistry expertise to identify new drug candidates for OneWorld Health's diarrheal disease program. Total contract value for Galapagos exceeds EUR3 million over two and a half years.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances